Please enable JavaScript to continue using this application.

Compare $CADL vs $GYRE | Chartloom

Compare

$CADL vs $GYRE

Candel Therapeutics Inc · Gyre Therapeutics Inc

CADL

Candel Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Compare $CADL vs $GYRE

Comparing Candel Therapeutics Inc and Gyre Therapeutics Inc

CADLCandel Therapeutics Inc

GYREGyre Therapeutics Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

GYREGyre Therapeutics Inc

Market cap

$643M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

16.8%

YTD performance

3.4%

52W performance

-3.6%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

GYRE

Detailed metrics comparison

CADL

Candel Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

CADL$728M

GYRE$643M

Enterprise Value

CADL$575M

GYRE$600M

Price

CADL$9.94

GYRE$7.04

P/E Ratio

CADLN/A

GYREN/A

P/S Ratio

CADL6,281.93x

GYRE5.39x

EV/Sales

CADL5,042.14x

GYRE5.03x

EV/EBITDA

CADL0.00x

GYRE286.88x

P/B Ratio

CADL6.18x

GYRE5.78x

P/FCF Ratio

CADLN/A

GYREN/A

EV/FCF

CADL-10.02x

GYRE-35.74x

PEG Ratio

CADLN/A

GYREN/A

Forward P/E (NTM)

CADLN/A

GYREN/A

Forward P/S (NTM)

CADLN/A

GYREN/A

Revenue (TTM)

CADL$0

GYRE$119M

Revenue Growth (YoY)

CADLN/A

GYRE16.8%

Forward Rev Growth

CADL371.1%

GYRE21.1%

Gross Margin (TTM)

CADL0.0%

GYRE94.3%

Operating Margin (TTM)

CADL0.0%

GYRE0.0%

EBITDA Margin (TTM)

CADL0.0%

GYRE-8.5%

Net Margin (TTM)

CADL0.0%

GYRE-15.5%

FCF Margin (TTM)

CADLN/A

GYRE-14.1%

Net Income (TTM)

CADL$-89M

GYRE$-18M

FCF (TTM)

CADL$-57M

GYRE$-17M

EPS (TTM)

CADL-$1.19

GYRE-$0.18

ROE (TTM)

CADL-8938.0%

GYRE-1584.0%

ROA (TTM)

CADL-5631.0%

GYRE-1014.0%

ROIC (TTM)

CADL-6512.0%

GYRE-1584.0%

Cash

CADL$202M

GYRE$43M

Debt

CADL$48M

GYRE$0

Net Cash/Debt

CADL$154M

GYRE$43M

Current Ratio (TTM)

CADL16.09x

GYRE4.26x

Quick Ratio (TTM)

CADL15.89x

GYRE3.64x

Debt/Equity (TTM)

CADL0.38x

GYRE0.00x

Debt/Assets (TTM)

CADL0.0%

GYRE0.0%

Interest Coverage (TTM)

CADLN/A

GYREN/A

Net Debt/EBITDA (TTM)

CADL0.00x

GYRE0.00x

Beta

CADL-0.28

GYRE2.46

52W Performance

CADL57.8%

GYRE-3.6%

YTD Performance

CADL82.7%

GYRE3.4%

% from 52W High

CADL-29.0%

GYRE-25.3%

% from 52W Low

CADL128.5%

GYRE29.4%

Asset Turnover (TTM)

CADL0.00x

GYRE0.70x

FCF Yield (TTM)

CADL-7.9%

GYRE-2.6%

Earnings Yield (TTM)

CADL-12.2%

GYRE-2.9%

Dividend Yield (TTM)

CADLN/A

GYREN/A

Rule of 40

CADL0.0

GYRE2.8

EV/GP/RG

CADLN/A

GYRE0.23

Ticker research

View CADL research View GYRE research

Metric	CADL Candel Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$728M	$643M
Enterprise Value	$575M	$600M
Price	$9.94	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	5.39x
EV/Sales	5,042.14x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	6.18x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$119M
Revenue Growth (YoY)	N/A	16.8%
Forward Rev Growth	371.1%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-8.5%
Net Margin (TTM)	0.0%	-15.5%
FCF Margin (TTM)	N/A	-14.1%
Net Income (TTM)	$-89M	$-18M
FCF (TTM)	$-57M	$-17M
EPS (TTM)	-$1.19	-$0.18
ROE (TTM)	-8938.0%	-1584.0%
ROA (TTM)	-5631.0%	-1014.0%
ROIC (TTM)	-6512.0%	-1584.0%
Financial Health
Cash	$202M	$43M
Debt	$48M	$0
Net Cash/Debt	$154M	$43M
Current Ratio (TTM)	16.09x	4.26x
Quick Ratio (TTM)	15.89x	3.64x
Debt/Equity (TTM)	0.38x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.46
52W Performance	57.8%	-3.6%
YTD Performance	82.7%	3.4%
% from 52W High	-29.0%	-25.3%
% from 52W Low	128.5%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.70x
FCF Yield (TTM)	-7.9%	-2.6%
Earnings Yield (TTM)	-12.2%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	2.8
EV/GP/RG	N/A	0.23
Ticker research	View CADL research	View GYRE research

Valuation

P/S Ratio

GYRE

5.39x

CADL

6,281.93x

EV/FCF

GYRE

-35.74x

CADL

-10.02x

Growth & revenue

Revenue Growth TTM

GYRE

16.8%

Forward Revenue Growth

CADL

371.1%

GYRE

21.1%

Profitability & performance

Gross Margin

GYRE

94.3%

CADL

0.0%

ROE

GYRE

-1584.0%

CADL

-8938.0%

FCF Yield %

GYRE

-2.6%

CADL

-7.9%

52-Week Performance

CADL

57.8%

GYRE

-3.6%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

CADL$728M

GYRE$643M

Enterprise Value

CADL$575M

GYRE$600M

Price

CADL$9.94

GYRE$7.04

P/E Ratio

CADLN/A

GYREN/A

P/S Ratio

CADL6,281.93x

GYRE5.39x

EV/Sales

CADL5,042.14x

GYRE5.03x

EV/EBITDA

CADL0.00x

GYRE286.88x

P/B Ratio

CADL6.18x

GYRE5.78x

P/FCF Ratio

CADLN/A

GYREN/A

EV/FCF

CADL-10.02x

GYRE-35.74x

PEG Ratio

CADLN/A

GYREN/A

Forward P/E (NTM)

CADLN/A

GYREN/A

Forward P/S (NTM)

CADLN/A

GYREN/A

Revenue (TTM)

CADL$0

GYRE$119M

Revenue Growth (YoY)

CADLN/A

GYRE16.8%

Forward Rev Growth

CADL371.1%

GYRE21.1%

Gross Margin (TTM)

CADL0.0%

GYRE94.3%

Operating Margin (TTM)

CADL0.0%

GYRE0.0%

EBITDA Margin (TTM)

CADL0.0%

GYRE-8.5%

Net Margin (TTM)

CADL0.0%

GYRE-15.5%

FCF Margin (TTM)

CADLN/A

GYRE-14.1%

Net Income (TTM)

CADL$-89M

GYRE$-18M

FCF (TTM)

CADL$-57M

GYRE$-17M

EPS (TTM)

CADL-$1.19

GYRE-$0.18

ROE (TTM)

CADL-8938.0%

GYRE-1584.0%

ROA (TTM)

CADL-5631.0%

GYRE-1014.0%

ROIC (TTM)

CADL-6512.0%

GYRE-1584.0%

Cash

CADL$202M

GYRE$43M

Debt

CADL$48M

GYRE$0

Net Cash/Debt

CADL$154M

GYRE$43M

Current Ratio (TTM)

CADL16.09x

GYRE4.26x

Quick Ratio (TTM)

CADL15.89x

GYRE3.64x

Debt/Equity (TTM)

CADL0.38x

GYRE0.00x

Debt/Assets (TTM)

CADL0.0%

GYRE0.0%

Interest Coverage (TTM)

CADLN/A

GYREN/A

Net Debt/EBITDA (TTM)

CADL0.00x

GYRE0.00x

Beta

CADL-0.28

GYRE2.46

52W Performance

CADL57.8%

GYRE-3.6%

YTD Performance

CADL82.7%

GYRE3.4%

% from 52W High

CADL-29.0%

GYRE-25.3%

% from 52W Low

CADL128.5%

GYRE29.4%

Asset Turnover (TTM)

CADL0.00x

GYRE0.70x

FCF Yield (TTM)

CADL-7.9%

GYRE-2.6%

Earnings Yield (TTM)

CADL-12.2%

GYRE-2.9%

Dividend Yield (TTM)

CADLN/A

GYREN/A

Rule of 40

CADL0.0

GYRE2.8

EV/GP/RG

CADLN/A

GYRE0.23

Ticker research

View CADL research View GYRE research

Metric	CADL Candel Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$728M	$643M
Enterprise Value	$575M	$600M
Price	$9.94	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	5.39x
EV/Sales	5,042.14x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	6.18x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$119M
Revenue Growth (YoY)	N/A	16.8%
Forward Rev Growth	371.1%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-8.5%
Net Margin (TTM)	0.0%	-15.5%
FCF Margin (TTM)	N/A	-14.1%
Net Income (TTM)	$-89M	$-18M
FCF (TTM)	$-57M	$-17M
EPS (TTM)	-$1.19	-$0.18
ROE (TTM)	-8938.0%	-1584.0%
ROA (TTM)	-5631.0%	-1014.0%
ROIC (TTM)	-6512.0%	-1584.0%
Financial Health
Cash	$202M	$43M
Debt	$48M	$0
Net Cash/Debt	$154M	$43M
Current Ratio (TTM)	16.09x	4.26x
Quick Ratio (TTM)	15.89x	3.64x
Debt/Equity (TTM)	0.38x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.46
52W Performance	57.8%	-3.6%
YTD Performance	82.7%	3.4%
% from 52W High	-29.0%	-25.3%
% from 52W Low	128.5%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.70x
FCF Yield (TTM)	-7.9%	-2.6%
Earnings Yield (TTM)	-12.2%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	2.8
EV/GP/RG	N/A	0.23
Ticker research	View CADL research	View GYRE research